AC Immune (NASDAQ:ACIU) CEO Andrea Pfeifer Sells 10,000 Shares

AC Immune (NASDAQ:ACIU) CEO Andrea Pfeifer sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $2.79, for a total value of $27,900.00. Following the completion of the sale, the chief executive officer owned 3,820,288 shares in the company, valued at approximately $10,658,603.52. This represents a 0.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

AC Immune Trading Down 0.7%

AC Immune stock opened at $2.77 on Tuesday. The company has a current ratio of 0.87, a quick ratio of 1.02 and a debt-to-equity ratio of 0.11. AC Immune has a 12 month low of $1.60 and a 12 month high of $4.00. The stock’s 50 day simple moving average is $2.95 and its two-hundred day simple moving average is $3.08. The firm has a market cap of $281.90 million, a PE ratio of -3.38 and a beta of 1.65.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01. AC Immune had a negative return on equity of 125.26% and a negative net margin of 1,788.02%.The business had revenue of $1.40 million for the quarter, compared to analyst estimates of $0.33 million. Analysts anticipate that AC Immune will post -0.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Wall Street Zen upgraded AC Immune from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. BTIG Research reiterated a “buy” rating and set a $8.00 target price on shares of AC Immune in a research report on Monday, May 4th. Weiss Ratings lowered AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 8th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $7.00 target price on shares of AC Immune in a research report on Friday, March 13th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, AC Immune presently has an average rating of “Hold” and a consensus target price of $7.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership lifted its holdings in AC Immune by 8.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after purchasing an additional 30,035 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in AC Immune by 82.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after purchasing an additional 176,701 shares in the last quarter. EFG International AG purchased a new position in AC Immune in the 4th quarter valued at $41,000. Marshall Wace LLP purchased a new position in AC Immune in the 4th quarter valued at $586,000. Finally, Goldman Sachs Group Inc. lifted its holdings in AC Immune by 46.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after purchasing an additional 5,920 shares in the last quarter. Hedge funds and other institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.